浙江大学 | 药学院 | English Version
     
     
朱峰 - 浙江大学
关于导师
朱峰博士

浙江大学 药学院 长聘教授（Tenured Professor）

爱思唯尔.《Computers in Biology and Medicine》.主编（Editor-in-Chief；IF = 4.589）

Web of Science h-index: 36 ； Scopus h-index: 38 ； Google Scholar h-index: 40

zhufeng@zju.edu.cn（常用邮箱），prof.zhufeng@gmail.com；0571-88208444
个人简介
研究兴趣：药物化学、药物设计、新药靶发现、生物信息学和系统生物学

运用人工智能（机器学习、深度学习等）、复杂网络分析等生物信息学手段和多组学（基因组、转录组、蛋白组、代谢组等）新技术，分析和发现具有治疗效用药物靶点的成药性和系统生物学特性，发展新颖的用于药靶发现的新型预测方法和面向全球的在线工具，并进一步研究（多靶点）药物与重要靶点的相互作用机制。
 学术任职与教育背景
    当前学术任职

  • 浙江大学 药学院 长聘教授（Tenured Professor），博士生导师，本科生学术导师

  • 爱思唯尔出版集团 《Computers in Biology and Medicine》 主编（Editor-in-Chief；IF = 4.589）

  • 浙江省生物信息学会 智能药学委员会 主任

  • 中国药理学会 分析药理学青年委员会 副主任，常务委员

  • 中国化学会 计算机化学委员会 委员

  • 中国药理学会 分析药理学委员会 委员

  • 中国细胞生物学会 功能基因组委员会 委员

  • 中国计算机学会 生物信息学委员会 委员

  • 重庆市 生物信息学会 副理事长

  • 浙江省 生物信息学会 理事

  • 浙江大学 竺可桢学院 专业导师

    • 曾任职和教育背景

  • 浙江大学 药学院 百人计划研究员，博士生导师

  • 重庆大学 药学院 教授，博士生导师

  • 重庆大学 创新药物研究中心 百人计划研究员，博士生导师

  • 新加坡国立大学 药学系 Research Fellow

  • 新加坡国立大学 药学系 Research Associate

  • 新加坡国立大学 亚洲研究中心和药学系 Research Assistant

  • 新加坡国立大学 药学系 博士

  • 北京师范大学 北京市光学重点实验室 硕士

  • 北京师范大学 物理系 学士
 奖励荣誉与人才计划
    代表性奖励和荣誉

  • 国家 万人计划 领军人才 入选者（2020）

  • 国家 四青人才 高层次专家 入选者（2014）

  • 科技部 创新人才推进计划 中青年科技创新领军人才 入选者（2019）

  • 浙江省 自然科学基金 杰出青年项目 获得者（2021）

  • 浙江省 高层次人才计划 省特聘专家 入选者（2018）

  • 中国 科学技术信息研究所 中国百篇最具影响国际学术论文榜单 入选者（2021）

  • 中国 同舟云全球学者库 全球顶尖前10万科学家 入选者（2022）

  • 美国 斯坦福大学 全球前2%顶尖科学家榜单 入选者（2020）

  • 九三学社 浙江省委 社会服务先进个人 获得者（2021）

  • 约翰威立出版社 高被引论文奖 Wiley-TCPA 获得者（2020）

  • 浙江省 普通高等学校 优秀博士毕业生 指导教师（2021）

  • 浙江省 普通高等学校 优秀硕士毕业生 指导教师（2020）

    • 其他奖励和荣誉

  • 科技部 创新人才推进计划 重点领域创新团队 核心成员（2019）

  • 重庆市 科学技术奖 科技进步一等奖 获得者（排名第四，2019）

  • 浙江省 挑战杯竞赛 三等奖 指导教师（2021）

  • 浙江大学 石华玉奖教金 一等奖 获得者（2021）

  • 浙江大学 江芷生物制药奖 优秀指导教师 获得者（2020）

  • 浙江大学 挑战杯竞赛 二等奖 指导教师（2021）

  • 重庆大学 唐立新优秀科研教师奖 三等奖 获得者（2014）

  • 浙江大学 药学院 年度十大科技进展 获得者（2022）

  • 浙江大学 药学院 年度先进工作者 获得者（2020）

  • 浙江大学 药学院 年度先进工作者 获得者（2019）
 教改项目资助（项目负责人、项目参与人等）
  • 2021年12月开始（项目负责人，省部级）：浙江省普通高校“十三五”新形态教材建设项目（2021-135-33）

  • 2021年01月开始（项目负责人，学校级）：中央教育教学改革基金研究生新形态教材编撰项目（zyjyjx-grazju-49）

  • 2020年06月开始（项目负责人，学校级）：中央教育教学改革基金本科新形态教材编撰项目（068-484607）

  • 2020年09月开始（项目参与人，学校级）：浙江大学研究生课程思政项目（1913039）
 科研项目资助（项目主持人、子课题主持、子课题骨干等）
    在研项目

  • 2020年10月开始（项目主持人，国家级）：国家“万人计划”领军人才项目（CWR-L-ZJU2020-ZF）

  • 2020年01月开始（子课题主持，国家级）：国家自然科学基金联合基金项目（U1909208）

  • 2019年01月开始（项目主持人，国家级）：国家自然科学基金面上项目（81872798）

  • 2021年01月开始（项目主持人，省部级）：浙江省自然科学基金“杰出青年”项目（LR21H300001）

  • 2021年05月开始（项目主持人，省部级）：损伤防治药物全军重点实验室基金项目（181201*194232101）

  • 2020年01月开始（子课题主持，省部级）：浙江省重点研发计划择优委托项目（2020C03010）

  • 2021年02月开始（项目主持人，学校级）：阿里巴巴-浙江大学未来数字医疗联合基金项目（ALIZJU202101）

    • 结题项目

  • 2014年06月开始（项目主持人，国家级）：国家四青人才项目（IRPC-Y-CQU2014-ZF）

  • 2016年08月开始（子课题主持，国家级）：国家重点研发计划精准医学重点专项（2016YFC0902200）

  • 2018年09月开始（子课题骨干，国家级）：国家重点研发计划精准医学重点专项（2018YFC0910500）

  • 2013年01月开始（项目主持人，国家级）：国家自然科学基金青年项目（81202459）

  • 2015年12月开始（项目主持人，省部级）：重庆市重大新药创制化药类主题专项（cstc2015zdcy-ztzx120003）

  • 2012年09月开始（项目主持人，省部级）：重庆市自然科学基金面上项目（cstc2012jjA10116）

  • 2017年07月开始（项目主持人，学校级）：浙江大学“百人计划”基金（ZJU2017070，考评杰出）

  • 2012年07月开始（项目主持人，学校级）：重庆大学“百人计划”基金（0903005203176，考评优秀）

  • 2014年06月开始（项目主持人，学校级）：中央高校基础科研跨学科重大项目（CDJZR14 46 88 01，结题优秀）

  • 2013年01月开始（项目主持人，学校级）：中央高校基础科研跨学科重点项目（CQDXWL-2012-Z003，结题优秀）

  • 2018年01月开始（项目主持人，学校级）：浙江大学青年科研创新专项基金（2018QNA7023）
 已发表的代表性研究工作 (*corresponding author; highlighted graphic abstract; PDF version of paper)
  1. J. B. Fu, Y. Zhang, Y. X. Wang, H. N. Zhang, J. Liu, J. Tang, Q. X. Yang, H. C. Sun, W. Q. Qiu, Y. H. Ma, Z. R. Li, M. Y. Zheng, F. Zhu*. Optimization of metabolomic data processing using NOREVA. Nature Protocols (当年影响因子: 13.491, 生物一区 TOP 期刊). 17(1): 129-151 (2022). PMID: 34952956.
    2. 杂志精选论文: 科技媒体及新闻报道:

  2. T. T. Fu, F. C. Li, Y. Zhang, J. Y. Yin, W. Q. Qiu, X. D. Li, X. G. Liu, W. W. Xin, C. Z. Wang, L. S. Yu, J. Q. Gao, Q. C. Zheng*, S. Zeng*, F. Zhu*. VARIDT 2.0: structural variability of drug transporter. Nucleic Acids Research (当年影响因子: 16.971, 生物一区 TOP 期刊). 50(D1): 1417-1431 (2022). PMID: 34747471.
    3. 科技媒体及新闻报道:

  3. X. N. Wang, F. C. Li, W. Q. Qiu, B. B. Xu, Y. L. Li, X. C. Lian, H. Y. Yu, Z. Zhang, J. X. Wang, Z. R. Li, W. W. Xue*, F. Zhu*. SYNBIP: synthetic binding proteins for research, diagnosis and therapy. Nucleic Acids Research (当年影响因子: 16.971, 生物一区 TOP 期刊). 50(D1): 560-570 (2022). PMID: 34664670.
    4. 科技媒体及新闻报道:

  4. J. Y. Yin, F. C. Li, Y. Zhou, M. J. Mou, Y. J. Lu, K. L. Chen, J. Xue, Y. C. Luo, J. B. Fu, X. He, J. Q. Gao, S. Zeng*, L. S. Yu*, F. Zhu*. INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Research (当年影响因子: 16.971, 生物一区 TOP 期刊). 49(D1): 1233-1243 (2021). PMID: 33045737.
    5. 科技媒体及新闻报道:

  5. J. Tang, X. L. Wu, M. J. Mou, C. Wang, L. D. Wang, F. C. Li, M. Y. Guo, J. Y. Yin, W. Q. Xie, X. N. Wang, Y. X. Wang, Y. B. Ding*, W. W. Xue*, F. Zhu*. GIMICA: host genetic and immune factors shaping human microbiota. Nucleic Acids Research (当年影响因子: 16.971, 生物一区 TOP 期刊). 49(D1): 715-722 (2021). PMID: 33045729.
    6. 科技媒体及新闻报道:

  6. Y. X. Wang, S. Zhang, F. C. Li, Y. Zhou, Y. Zhang, Z. W. Wang, R. Y. Zhang, J. Zhu, Y. X. Ren, Y. Tan, C. Qin, Y. H. Li, X. X. Li, Y. Z. Chen*, F. Zhu*. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research (当年影响因子: 11.501, 生物一区 TOP 期刊). 48(D1): 1031-1041 (2020). PMID: 31691823.
    7. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.15% in 2021.
    科技媒体及新闻报道:

  7. Q. X. Yang, Y. X. Wang, Y. Zhang, F. C. Li, W. Q. Xia, Y. Zhou, Y. Q. Qiu, H. L. Li, F. Zhu*. NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data. Nucleic Acids Research (当年影响因子: 11.501, 生物一区 TOP 期刊). 48(W1): 436-448 (2020). PMID: 32324219.
    8. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.17% in 2022.
    科技媒体及新闻报道:

  8. J. Y. Yin, W. Sun, F. C. Li, J. J. Hong, X. X. Li, Y. Zhou, Y. J. Lu, M. Z. Liu, X. Zhang, N. Chen, X. P. Jin, J. Xue, S. Zeng*, L. S. Yu*, F. Zhu*. VARIDT 1.0: variability of drug transporter database. Nucleic Acids Research (当年影响因子: 11.501, 生物一区 TOP 期刊). 48(D1): 1042-1050 (2020). PMID: 31495872.
    9. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.98% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.33% in 2021.
    科技媒体及新闻报道:

  9. Y. H. Li, C. Y. Yu, X. X. Li, P. Zhang, J. Tang, Q. X. Yang, T. T. Fu, X. Y. Zhang, X. J. Cui, G. Tu, Y. Zhang, S. Li, F. Y. Yang, Q. Sun, C. Qin, X. Zeng, Z. Chen, Y. Z. Chen*, F. Zhu*. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Research (当年影响因子: 11.561, 生物一区 TOP 期刊). 46(D1): 1121-1127 (2018). PMID: 29140520.
    10. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.21% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.15% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.16% in 2019.
    领域内专家评论:
    • Introduced by OMICTOOLS as "useful for facilitating patient focused research, discovery and clinical investigations of the targeted therapeutics".

  10. B. Li, J. Tang, Q. X. Yang, S. Li, X. J. Cui, Y. H. Li, Y. Z. Chen, W. W. Xue, X. F. Li, F. Zhu*. NOREVA: normalization and evaluation of MS-based metabolomics data. Nucleic Acids Research (当年影响因子: 10.162, 生物一区 TOP 期刊). 45(W1): 162-170 (2017). PMID: 28525573.
    11. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.84% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.71% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.75% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.27% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 2.98% in 2018.
    领域内专家评论:
    • Introduced by OMICTOOLS as "provided valuable guidance to the selection of suitable algorithm in metabolomics".
    • Discussed in StackExchange as "works fine" and "corrections for batches without QC options".

  11. F. Zhu, Z. Shi, C. Qin, L. Tao, X. Liu, F. Xu, L. Zhang, Y. Song, X. H. Liu, J. X. Zhang, B. C. Han, P. Zhang, Y. Z. Chen*. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Research (当年影响因子: 8.026, 生物一区 TOP 期刊). 40(D1): 1128-1136 (2012). PMID: 21948793.
    12. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.77% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.69% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.66% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.60% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 0.62% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 0.31% in 2017.

  12. F. Zhu, B. C. Han, P. Kumar, X. H. Liu, X. H. Ma, X. N. Wei, L. Huang, Y. F. Guo, L. Y. Han, C. J. Zheng, Y. Z. Chen*. Update of TTD: therapeutic target database. Nucleic Acids Research (当年影响因子: 7.479, 生物一区 TOP 期刊). 38(D1): 787-791 (2010). PMID: 19933260.
    13. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.95% in 2017.

  13. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. H. Ma, J. Jia, Y. Tan, C. Cui, J. S. Lin, C. Y. Tan, Y. Y. Jiang*, Y. Z. Chen*. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proceedings of the National Academy of Sciences of the United States of America (当年影响因子: 9.432, 综合性一区 TOP 期刊). 108(31): 12943-12948 (2011). PMID: 21768386.
    14. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.97% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.98% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.93% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.94% in 2019.
    • The Percentile in Subject Area shown in InCites™ was 1.16% in 2018.
    • The Percentile in Subject Area shown in InCites™ was 1.91% in 2017.
    领域内专家评论: 科技媒体及新闻报道:

  14. S. Zhang, K. Amahong, C. Y. Zhang, F. C. Li, J. Q. Gao, Y. Q. Qiu*, F. Zhu*. RNA-RNA interactions between SARS-CoV-2 and host benefit viral development and evolution during COVID-19 infection. Briefings in Bioinformatics (当年影响因子: 11.622, 生物一区 TOP 期刊). doi: 10.1093/bib/bbab397 (2022). PMID: 34585235.

  15. S. Zhang, Y. Zhou, Y. N. Wang, Z. W. Wang, Q. T. Xiao, Y. Zhang, Y. Lou, Y. Q. Qiu*, F. Zhu*. The mechanistic, diagnostic and therapeutic novel nucleic acids for hepatocellular carcinoma emerging in past score years. Briefings in Bioinformatics (当年影响因子: 11.622, 生物一区 TOP 期刊). 22(2): 1860-1883 (2021). PMID: 32249290.

  16. J. B. Fu, Y. Zhang, J. Liu, X. C. Lian, J. Tang, F. Zhu*. Pharmacometabonomics: data processing and statistical analysis. Briefings in Bioinformatics (当年影响因子: 11.622, 生物一区 TOP 期刊). 22(5): bbab138 (2021). PMID: 33866355.

  17. J. Tang, M. J. Mou, Y. X. Wang, Y. C. Luo, F. Zhu*. MetaFS: performance assessment for biomarker discovery in metaproteomics. Briefings in Bioinformatics (当年影响因子: 11.622, 生物一区 TOP 期刊). 22(3): bbaa105 (2021). PMID: 32510556.

  18. Y. H. Li, X. X. Li, J. J. Hong, Y. X. Wang, J. B. Fu, H. Yang, C. Y. Yu, F. C. Li, J. Hu, W. W. Xue, Y. Y. Jiang, Y. Z. Chen*, F. Zhu*. Clinical trials, progression-speed differentiating features, and swiftness rule of the innovative targets of first-in-class drugs. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(2): 649-662 (2020). PMID: 30689717.
    19. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.49% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.09% in 2021.

  19. J. Tang, J. B. Fu, Y. X. Wang, B. Li, Y. H. Li, Q. X. Yang, X. J. Cui, J. J. Hong, X. F. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. ANPELA: analysis and performance-assessment of the label-free quantification workflow for metaproteomic studies. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(2): 621-636 (2020). PMID: 30649171.
    20. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.20% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.05% in 2021.

  20. Q. X. Yang, B. Li, J. Tang, X. J. Cui, Y. X. Wang, X. F. Li, J. Hu, Y. Z. Chen, W. W. Xue, Y. Lou, Y. Q. Qiu*, F. Zhu*. Consistent gene signature of schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(3): 1058-1068 (2020). PMID: 31157371.
    21. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.61% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.19% in 2021.

  21. J. J. Hong, Y. C. Luo, M. J. Mou, J. B. Fu, Y. Zhang, W. W. Xue, T. Xie, L. Tao*, Y. Lou*, F. Zhu*. Convolutional neural network-based annotation of bacterial type IV secretion system effectors with enhanced accuracy and reduced false discovery. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(5): 1825-1836 (2020). PMID: 31860715.
    22. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.22% in 2022.

  22. Z. J. Han, W. W. Xue, L. Tao, Y. Lou, Y. Q. Qiu*, F. Zhu*. Genome-wide identification and analysis of the eQTL lncRNAs in multiple sclerosis based on RNA-seq data. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(3): 1023-1037 (2020). PMID: 31323688.

  23. J. Tang, Y. X. Wang, J. B. Fu, Y. Zhou, Y. C. Luo, Y. Zhang, B. Li, Q. X. Yang, W. W. Xue, Y. Lou, Y. Q. Qiu*, F. Zhu*. A critical assessment of the feature selection methods used for biomarker discovery in current metaproteomic studies. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(4): 1378-1390 (2020). PMID: 31197323.

  24. J. J. Hong, Y. C. Luo, Y. Zhang, J. B. Ying, W. W. Xue, T. Xie, L. Tao*, F. Zhu*. Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(4): 1437-1447 (2020). PMID: 31504150.
    25. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.54% in 2022.

  25. Q. X. Yang, J. J. Hong, Y. Li, W. W. Xue, S. Li*, H. Yang*, F. Zhu*. A novel bioinformatics approach to identify the consistently well-performing normalization strategy for current metabolomic studies. Briefings in Bioinformatics (当年影响因子: 9.101, 生物一区 TOP 期刊). 21(6): 2142-2152 (2020). PMID: 31776543.

  26. S. Zhang, F. Zhu*. Comment on microRNA mimics or inhibitors as antiviral therapeutic approaches against COVID-19. Drugs (当年影响因子: 9.542, 医学二区 TOP 期刊). 81(14): 1691-1692 (2021). PMID: 34453690.

  27. Y. X. Wang, F. C. Li, Y, Zhang, Y. Zhou, Y. Tan, Y. Z. Chen*, F. Zhu*. Databases for the targeted COVID-19 therapeutics. British Journal of Pharmacology (当年影响因子: 7.730, 医学二区 TOP 期刊). 177(21): 4999-5001 (2020). PMID: 32845521.

  28. J. Y. Yin, X. X. Li, F. C. Li, Y. J. Lu, S. Zeng*, F. Zhu*. Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease. Computational and Structural Biotechnology Journal (当年影响因子: 7.271, 生物二区期刊). 19: 2318-2328 (2021). PMID: 33995923.

  29. J. Tang, Y. X. Wang, Y. C. Luo, J. B. Fu, Y. Zhang, Y. Li, Z. Y. Xiao, Y. Lou, Y. Q. Qiu*, F. Zhu*. Computational advances of tumor marker selection and sample classification in cancer proteomics. Computational and Structural Biotechnology Journal (当年影响因子: 6.018, 生物二区 TOP 期刊). 18: 2012-2025 (2020). PMID: 32802273.

  30. T. T. Fu, G. Tu, M. Ping, G. X. Zheng, F. Y. Yang, J. Y. Yang, Y. Zhang, X. J. Yao, W. W. Xue*, F. Zhu*. Subtype selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors. Acta Pharmacologica Sinica (当年影响因子: 6.150, 医学一区 TOP 期刊). 42(8): 1354-1367 (2021). PMID: 33122823.

  31. J. Tang, J. B. Fu, Y. X. Wang, Y. C. Luo, Q. X. Yang, B. Li, G. Tu, J. J. Hong, X. J. Cui, Y. Z. Chen, L. X. Yao, W. W. Xue, F. Zhu*. Simultaneous improvement in the precision, accuracy and robustness of label-free proteome quantification by optimizing data manipulation chains. Molecular & Cellular Proteomics (当年影响因子: 5.236, 生物二区 TOP 期刊). 18(8): 1683-1699 (2019). PMID: 31097671.
    32. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.12% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.81% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.57% in 2020.

  32. F. C. Li, Y. Zhou, X. Y. Zhang, J. Tang, Q. X. Yang, Y. Zhang, Y. C. Luo, J. Hu*, W. W. Xue, Y. Q. Qiu, Q. J. He, B. Yang, F. Zhu*. SSizer: determining the sample sufficiency for comparative biological study. Journal of Molecular Biology (当年影响因子: 5.067, 生物二区 TOP 期刊). 432(11): 3411-3421 (2020). PMID: 32044343.

  33. Y. Zhang, J. B. Ying, J. J. Hong, F. C. Li, T. T. Fu, F. Y. Yang, G. X. Zheng, X. J. Yao, Y. Lou, Y. Q. Qiu, W. W. Xue*, F. Zhu*. How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from Trichostatin A enantiomers based on molecular dynamics. ACS Chemical Neuroscience (当年影响因子: 4.211, 化学二区 TOP 期刊). 10(5): 2467-2480 (2019). PMID: 30784262.
    34. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 1.99% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 1.19% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.74% in 2020.
    封面论文:

  34. W. W. Xue, F. Y. Yang, P. P. Wang, G. X. Zheng, Y. Z. Chen, X. J. Yao, F. Zhu*. What contributes to serotonin-norepinephrine reuptake inhibitors' dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by MD simulation. ACS Chemical Neuroscience (当年影响因子: 4.211, 化学二区 TOP 期刊). 9(5): 1128-1140 (2018). PMID: 29300091.
    35. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 0.18% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 0.14% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 0.21% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 0.29% in 2019.

  35. P. P. Wang, X. Y. Zhang, T. T. Fu, S. Li, B. Li, W. W. Xue*, X. J. Yao, Y. Z. Chen, F. Zhu*. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chemical Neuroscience (当年影响因子: 4.348, 化学二区 TOP 期刊). 8(6): 1416-1428 (2017). PMID: 28557437.  
    36. ESI高被引或扩展高被引论文:
    • The Percentile in Subject Area shown in InCites™ was 2.17% in 2022.
    • The Percentile in Subject Area shown in InCites™ was 1.48% in 2021.
    • The Percentile in Subject Area shown in InCites™ was 1.80% in 2020.
    • The Percentile in Subject Area shown in InCites™ was 1.32% in 2019.

  36. F. Y. Yang, G. X. Zheng, T. T. Fu, X. F. Li, G. Tu, Y. H. Li, X. J. Yao, W. W. Xue*, F. Zhu*. Prediction of binding mode and resistance profile for dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase associated ribonuclease H. Physical Chemistry Chemical Physics (当年影响因子: 4.123, 化学二区 TOP 期刊). 20(37): 23873-23884 (2018). PMID: 29947629.
    37. 封底论文:

  37. F. Zhu, L. Y. Han, C. J. Zheng, B. Xie, M. T. Tammi, S. Y. Yang, Y. Q. Wei, Y. Z. Chen*. What are next generation innovative therapeutic targets? Clues from genetic, structural, physicochemical and system profiles of successful targets. Journal of Pharmacology and Experimental Therapeutics (当年影响因子: 3.867, 医学二区 TOP 期刊). 330(1): 304-315 (2009). PMID: 19357322.
    38. 所构建方法的临床或实验验证:
    • Pasireotide targeting Somatostatin receptor 1 was approved by FDA in 2011.
    • Fingolimod targeting S1P receptor was approved by FDA in 2010.
    • Ecallantide targeting Plasma Kallikrein was approved by FDA in 2009.
    • Cinryze targeting C1 esterase was approved by FDA in 2009.
    • Icatibant targeting BK-2 receptor was approved by FDA in 2008.
    • Plerixafor targeting CXCR4 was approved by FDA in 2008.

  38. Q. X. Yang, Y. X. Wang, F. C. Li, S. Zhang, Y. C. Luo, Y. Li, J. Tang, B. Li, Y. Z. Chen, W. W. Xue, F. Zhu*. Identification of the gene signature reflecting schizophrenia's etiology by constructing artificial intelligence-based method of enhanced reproducibility. CNS Neuroscience & Therapeutics (当年影响因子: 3.394, 医学二区期刊). 25(9): 1054-1063 (2019). PMID: 31350824.
    39. 封面论文:

  39. Z. J. Han, W. W. Xue, L. Tao, F. Zhu*. Identification of novel immune-relevant drug target genes for alzheimer's disease by combining ontology inference with network analysis. CNS Neuroscience & Therapeutics (当年影响因子: 3.495, 医学二区期刊). 24(12): 1253-1263 (2018). PMID: 30106219.
    40. 奖励与荣誉:
    • Wiley Top Cited Paper Award (2020).
    封面论文:

 已获批专利与著作权
  1. F. Zhu, M. J. Mou, J. Tang, Y. X. Wang, et al. 软件著作权 2021SR0027303, 中华人民共和国国家版权局.
    A Software Tool for Selecting Metaproteomic Features Based on Performance Assessment (2021)

  2. F. Zhu, J. Y. Yin, F. C. Li, X. X. Li, et al. 软件著作权 2021SR0822567, 中华人民共和国国家版权局.
    A Software Tool for Constructing Phylogenetic Tree Describing the Homology among Drug Transporters (2021)

  3. F. Zhu, F. C. Li, Y. Zhou, X. Y. Zhang. 软件著作权 2021SR0826823, 中华人民共和国国家版权局.
    A Software Tool for Determining Sample Sufficiency for Comparative Biological Study (2021)

  4. F. Zhu, S. Zeng, J. Y. Yin, F. C. Li. 软件著作权 2020SR0275172, 中华人民共和国国家版权局.
    A Software Tool for Analyzing the Interplay among the Variabilities of Drug Transporters (2020)

  5. F. Zhu, Y. X. Wang, Y. Z. Chen, S. Zhang, et al. 软件著作权 2020SR0526446, 中华人民共和国国家版权局.
    A Software Tool for Integrating the Epigenetics with the Protein-Protein Interactions of Drug Target (2020)

  6. F. Zhu, Y. X. Wang, S. Zhang, F. C. Li, et al. 软件著作权 2020SR0527384, 中华人民共和国国家版权局.
    A Software Tool for Strictly Validating the Primary Drug Target and Conducting Network Analysis (2020)

  7. F. Zhu, Y. X. Wang, S. Zhang, F. C. Li, et al. 软件著作权 2020SR0528155, 中华人民共和国国家版权局.
    A Software Tool for Strictly Identifying the Primary Therapeutic Target of the Drugs in Clinical Trial (2020)

  8. F. Zhu, J. J. Hong, J. Hu, L. Tao. 软件著作权 2020SR0274064, 中华人民共和国国家版权局.
    A Software Tool for Discovering the Bacterial Type-IV Secreting System Effector Protein (2019)

  9. F. Zhu, J. Tang, J. B. Fu, Y. X. Wang. 软件著作权 2020SR0274135, 中华人民共和国国家版权局.
    A Software Tool for Assessing Label-free Proteome Quantification from Multiple Perspectives (2019)

  10. F. Zhu, F. C. Li, S. Zhang, Y. X. Wang, et al. 软件著作权 2020SR0525443, 中华人民共和国国家版权局.
    A Software Tool for Discovering the Novel Drug Scaffold Based on Biomarker Identification (2019)

  11. F. Zhu, F. C. Li, S. Zhang, Y. X. Wang, et al. 软件著作权 2020SR0528147, 中华人民共和国国家版权局.
    A Software Tool for Identifying the Tissue-Specific Distribution Pattern of Therapeutic Target (2018)

  12. F. Zhu, Q. X. Yang, B. Li, Y. X. Wang. 软件著作权 2020SR0275177, 中华人民共和国国家版权局.
    A Software Tool for Evaluating Mass-spectrometry-based Metabolomic Data from Multiple Perspectives (2017)

  13. F. Zhu, S. Zhang, F. C. Li, Y. X. Wang, et al. 软件著作权 2020SR0528618, 中华人民共和国国家版权局.
    A Software Tool for Associating the Disease-Relevant Signaling Pathway with Therapeutic Target (2016)
 承办或（参与）组织的学术会议暨国际/国内学术会议任职情况
 国际/国内学术会议邀请报告（大会主题报告、邀请报告等）
 杂志评审（十二本代表性杂志）
Nucleic Acids Res (IF = 16.971); Med Res Rev (IF = 12.944); Br J Pharmacol (IF = 8.739);
Nat Protoc (IF = 13.491); Brief Bioinform (IF = 11.622); Bioinformatics (IF = 6.937);
Proc Natl Acad Sci U S A (IF = 11.206); Anal Chem (IF = 6.986); Mol Pharmaceut (IF = 4.939);
J Med Chem (IF = 7.446); Pharmacol Res (IF = 7.658); J Chem Inf Model (IF = 4.956)
 杂志副主编、编委或主题编辑
Front Pharmacol (IF = 5.810); Comput Biol Med (IF = 4.589); J Alzheimers Dis (IF = 4.472);
Curr Gene Ther (IF = 4.391); Protein Pept Lett (IF = 1.890); Prog Pharm Sci (IF = N.A.)
IDRB: Innovative Drug Research and Bioinformatics Group


创新药物研究与生物信息学实验室 (IDRB)   版权所有
地址：浙江省杭州市西湖区余杭塘路866号，浙江大学紫金港校区；邮编：310058。
联系电话：0571－88208444
ICP证：浙ICP备18036997号-1

本网站最新更新时间：